Diligence memo · auto-generated · as of July 2, 2026
Pluto Biosciences, Inc.
Pluto Biosciences, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Pluto Biosciences, Inc. operates in Biotech / Pharma, based in Denver.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pluto Biosciences, Inc. has raised $7.7M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.7M on 2023-05-01.
Most recent recorded round closed around 2025-04-21.
Valuation (modeled)modeled
Provath models Pluto Biosciences, Inc. at approximately $9.4M (range $2.2M–$20M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.63× the median modeled value of Seed Biotech / Pharma companies in 2025–2027 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 22 months.
Last raise 14 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 58% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 33% of those peers.
Closest niche peers: Chirality Biosciences, Inc., Spearhead Bio, Inc., PharmaWaste Ventures, LLC, Catch Bio, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.